Efficacy, safety and dose-response of pramipexole in Japanese patients with primary restless legs syndrome: Randomized trial

Neuropsychobiology

Volumn 63, Issue 1, 2010, Pages 35-42

  Inoue, Yuichi ^a,b   Kuroda, Kenji ^d   Hirata, Koichi ^e   Uchimura, Naohisa ^f   Kagimura, Tatsuo ^c   Shimizu, Tetsuo ^g  

^a NEUROPSYCHIATRIC RESEARCH INSTITUTE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^d Hannan Hospital   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f KURUME UNIVERSITY   (Japan)

^g AKITA UNIVERSITY   (Japan)

Author keywords

Early response; International Restless Legs Syndrome Study Group Rating Scale; Pittsburgh Sleep Quality Index; Pramipexole; Restless legs syndrome

Indexed keywords

CLONAZEPAM; PLACEBO; PRAMIPEXOLE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; JAPANESE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PREDICTION; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESS LEGS SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOTHIAZOLES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX;

EID: 78049477494     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322289     Document Type: Article

References (36)

1. Ekbom KA: Restless legs syndrome. Neurology 1960; 10:868-873.
2. Kawauchi A, Inoue Y, Hashimoto T, Tachiba-na N, Shirakawa S, Mizutani Y, Ono T, Miki T: Restless legs syndrome in hemodialysis patients: health-related quality of life and laboratory data analysis. Clin Nephrol 2006; 66:440-446.
3. Nomura T, Inoue Y, Kusumi M, Uemura Y, Nakashima K: Prevalence of restless legs syndrome in a rural community in Japan. Mov Disord 2008; 23: 2363-2369.
4. Williamson L, Yein K: Potential failure of contraceptive efficacy in a patient taking methotrexate. Rheumatology 2005; 44: 14 61-1462 .
5. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K: Prevalence and risk factors of RLS in an elderly population: the MEMO Study. Neurology 2000; 54:1064-1068.
6. Ohayon M, Rot h T: Preva lence of rest less legs syndrome and periodic limb movements disorder in the general population. J Psychosom Res 2002; 53 : 547-554.
7. Nomura T, Inoue Y, Kusumi M, Oka Y, Na-kashima K: Email-based epidemiological surveys on restless legs syndrome in Japan. Sleep Biol R hythms 2008; 6: 139-145.
8. Earley CJ: Restless legs syndrome. N Engl J Med 20 03; 348: 2103-2109.
9. Winkelmann J, Prager M, Lieb R, Pfister H, Spiegel B, Wittchen H-U, Holsboer F, Trenk-walder C, Ströhle A: 'Anxietas tibiarum': depression and anxiety disorders in patients with restless legs syndrome. J Neurol 2005; 252: 67-71.
10. Sevim S, Dogu O, Kaleagasi H, Aral M, Me-tin O, Çamdeviren H: Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population-based survey. J Neurol Neurosurg Psychiatry 2004; 75: 226-230.
11. Brand S, Lehtinen A, Hatzinger M, Hols-boer-Trachsler E: Comparison of sleep EEG profiles of patients suffering from restless legs syndrome and depressive symptoms, and major depressive disorders. Neuropsy-chobiology 2010; 61:41-48.
12. Ulfberg J, Nyström B, Carter N, Edling C: Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001; 16:1159-1163.
13. Winkelman JW, Shahar E, Sharief I, Gottlieb DJ: Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Healt h Study. Neurolog y 2008; 70: 35-4 2.
14. Abetz L, Allen R, Follet A, Washburn T, Ear-ley C, Kirsch J, Knight H: Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004; 26: 925-935.
15. Allen A: Dopamine and iron in the patho-physiology of restless legs syndrome (RLS). Sleep Med 2004; 5:385-391.
16. Chesson AL Jr, Wise M, Davila D, Johnson S, Littner M, McDowel l A nderson W, Ha r tse K, Rafecas J: Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. Sleep 1999; 22:961-968.
17. Littner MR, Kushida C, Anderson WM, Bailey D, Berry RB, Hirshkowitz M, Kapen S, Kramer M, Lee-Chiong T, Li KK, Loube DL, Morgenthaler T, Wise M: Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004; 27:557-559.
18. Silber MH, Ehrenberg BL, Allen RP, Buch-fuhrer MJ, Earley CJ, Hening WA, Rye DB: An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004; 79: 916-922.
19. McCrink L, Allen R P, Wolowacz S, Sherrill B, Connolly M, K irsch J: Predictors of hea lth-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med 2007; 8:73-83.
20. Becker PM, Ondo W, Sharon D: Encouraging initial response of restless legs syndrome to pramipexole. Neurology 1998; 51: 1221-1223.
21. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B: Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999; 52 : 93 8-943.
22. Stiasny-Kolster K, Oertel WH: Low-dose pramipexole in the management of restless legs syndrome: an open-label trial. Neuro-psychobiology 2004; 50:65-70.
23. Winkelman JW, Sethi KD, Kushida CA, Becker PM, Koester J, Cappola JJ, Reess J: Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006; 67:1034-1039.
24. Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, Koester J, Reess J: Efficacy and safety of pramipexole in idio-pathic restless legs syndrome: a polysomno-graphic dose-finding study - the PRELUDE Study. Sleep Med 2006; 7:407-417.
25. Ferini-Strambi L, Aarskog D, Partinen M, Chaudhuri KR, Sohr M, Verri D, Albrecht S: Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled tria l. Sleep Med 2008; 9: 874-881.
26. Merlino G, Dolso P, Canesin R, Cancelli I, Valente M, Gigli GL: The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial. Neuropsychobiolog y 2006; 54: 195-200.
27. Manconi M, Ferri R, Zucconi M, Oldani A, Fantini ML, Castronovo V, Ferini-Strambi L: First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med 2007; 8:491-497.
28. Inoue Y, Hirata K, Kuroda K, Fujita M, Shi-mizu T, Emura N, Uchimura N, Kagimura T, Sha K, Nozawa T: Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: a polysomno-graphic randomized, double-blind, placebo-controlled study. Sleep Med 2010; 11: 11-16.
29. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C, International Restless Legs Syndrome Study Group: Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003; 4:121-132.
30. Oertel WH, Stiasny-Kolster K, Bergtholdt B, Hallström Y, Albo J, Leissner L, Schindler T, Koester J, Reess J: Efficacy of pramipexole in restless legs syndrome: a six-week, multi-center, randomized, double-blind study (ef-fect-RLS study). Mov Disord 2007; 22:213-219.
31. Allen RP, Picchietti D, Hening WA, Trenk-walder C, Walters AS, Montplaisi J, Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health, International Restless Legs Syndrome Study Group: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101-119.
32. Morgan JC, Sethi KD: Efficacy and safety of pramipexole in restless legs syndrome. Curr Neurol Neurosci Rep 2007; 7: 273-277.
33. Takegami M, Suzukamo Y, Wakita T, Nogu-chi H, Chin K, Kadotani H, Inoue Y: Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on item response theory. Sleep Med 2009; 10:556-565.
34. Doi Y, Minowa M, Uchiyama M, Okawa M, Kim K, Shibui K, Kamei Y: Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. Psychiatry Res 2000; 97: 165-172.
35. García-Borreguero D, Allen R P, Benes H, Earley C, Happe S, Hög l B, Kohnen R, Paulus W, Rye D, Winkelmann J: Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Dis-ord 2007; 22(suppl 18):S476-S484.
36. Cornelius JR, Tippmann-Peikert M, Slo-cumb NL, Frerichs CF, Silber MH: Impulse control disorders with the use of dopaminer-gic agents in restless legs syndrome: a case-control study. Sleep 2010; 33: 81-87.